Studies demonstrated that chronic renal failure (CRF) affects the expression and activity of intestinal, hepatic, and renal drug transporters. Such drug transporters are expressed in brain cells and at the blood-brain barrier (BBB), where they limit the entry and distribution of drugs in the brain. Perturbations in brain drug transporter equilibrium by CRF could lead to central drug toxicity. This study evaluates how CRF affects BBB drug transporters using a 5/6 nephrectomized rat model. Protein and mRNA expression of influx transporters [organic anion-transporting polypeptide (Oatp), organic anion transporter (Oat)] and efflux transporters [P-glycoprotein (P-gp), multidrug resistance-related protein (Mrp), breast cancer resistance protein (Bcrp)] were measured in CRF and control rat brain. Intracerebral accumulation of radiolabeled benzylpenicillin, digoxin, doxorubicin, and verapamil was used to evaluate BBB drug permeability. Protein expression of the transporters was evaluated in rat brain endothelial cells (RBECs) and astrocytes incubated with control and CRF rat serum. We demonstrated significant decreases (30-50%) in protein and mRNA levels of Bcrp, Mrp2 to -4, Oat3, Oatp2 and -3, and P-gp in CRF rat brain biopsies, as well as in astrocytes and RBECs incubated with CRF serum. These decreases did not correlate with in vivo changes because BBB permeability of benzylpenicillin was decreased by 30% in CRF rats, whereas digoxin, doxorubicin, and verapamil permeabilities were unchanged. It thus seems that even with decreased drug transporters, BBB integrity and function is conserved in CRF.
Introduction
In recent years, many studies have demonstrated that chronic renal failure (CRF) significantly affects the expression and activity of intestinal, hepatic, and renal drug transporters via uremic mediators, thus altering the pharmacokinetics of many drugs (Huang et al., 2000; Laouari et al., 2001; Sun et al., 2004 Sun et al., , 2006 Naud et al., 2007 Naud et al., , 2008 Naud et al., , 2011 . Such drug transporters are also expressed in brain cells and at the blood-brain barrier (BBB) where they limit the entry and distribution of drugs in the brain ( Fig. 1) (Löscher and Potschka, 2005a,b,c; Ohtsuki and Terasaki, 2007) . Two major drug transporter families have been identified: ATP-binding cassette (ABC) transporters and solute carriers. The most important ABC transporters at the BBB are multidrug resistance related proteins (Mrp), breast cancer resistance protein (Bcrp), and P-glycoprotein (P-gp). Bcrp, Mrp2 to Mrp5, and P-gp are expressed on the luminal side, and they mediate the efflux of molecules from the brain capillary cell into the blood Löscher and Potschka, 2005c; Deeken and Löscher, 2007; Oswald et al., 2007; Eyal et al., 2009) . Mrp4 was also found on the abluminal side of bovine brain capillaries, where it is thought to mediate the efflux of molecules from the capillary cell into the brain, but this was not reported in rat and human brain Löscher and Potschka, 2005c; Deeken and Löscher, 2007; Oswald et al., 2007) . For solute carriers, the most important at the BBB are the organic anion transporter 3 (Oat3) and the organic anion-transporting proteins 2 and 3 (Oatp2-3). Oat3 is located on both membranes and mediates drug efflux from the brain into the blood (Kikuchi et al., 2003; Mori et al., 2003 Mori et al., , 2004 Löscher and Potschka, 2005c; Deeken and Löscher, 2007; Oswald et al., 2007) . Furthermore, it was recently hypothesized that Oat3 is also implicated in the influx of drugs from the blood to the brain (Ose et al., 2009) . Oatp2 is expressed at the luminal and abluminal membranes, whereas Oatp3 was found only at the luminal membrane of brain capillary cells, and they both mediate bidirectional transport of drugs (Löscher and Potschka, 2005c; Deeken and Löscher, 2007; Ohtsuki and Terasaki, 2007; Ose et al., 2010) . Perturbations in brain drug transporter equilibrium caused by CRF could lead to central toxicity of drugs.
To this day, there are no studies reporting the effects of CRF on brain drug transporters. However, indirect evidence suggests that CRF could be implicated in modulating their expression. Indeed, neurotoxicity of cephalosporin and penicillin derivates was reported in patients with altered renal function despite normal plasma concentrations (Chatellier et al., 2002; Ferrara et al., 2003; Alpay et al., 2004) . Drug transporters expressed at the BBB normally prevent the entry of these drugs into the brain (Kikuchi et al., 2003) . It was demonstrated that ␤-lactam antibiotics and cephalosporins are substrates of Oat3 and Mrps in the kidney and the brain (Kikuchi et al., 2003; Ueo et al., 2005; Ci et al., 2007; Nozaki et al., 2007) . It is noteworthy that Oat3 is also known to extract at least three uremic toxins from the brain: p-aminohippuric acid (PAH), indoxyl sulfate (IS), and 3-carboxyl-4-methyl-5-propyl-2-furonapropionate (CMPF) (Ohtsuki et al., 2002; Kikuchi et al., 2003; Tahara et al., 2005; Deguchi et al., 2006) . Finally, it was demonstrated that central and systemic inflammation, which are present in CRF (Oettinger et al., 1994; Sunder-Plassmann et al., 1994; Ziesche et al., 1994; Akahoshi et al., 1995; Higuchi et al., 1997) , can down-regulate the expression of P-gp at the BBB and in the liver, leading to drug accumulation in the brain and plasma (Zhao et al., 2002; Goralski et al., 2003; Petrovic et al., 2007) .
The objective of this study was to investigate the effects of CRF on the expression and activity of the major drug transporters expressed at the BBB and in the brain. To address this, we have measured 1) the protein and mRNA expressions of Oat3, Oatp2-3, Mrp2-4-5, and P-gp in brain tissue biopsies from CRF and control rats; 2) the protein expression of the same transporters in rat astrocytes and rat brain endothelial cells (RBECs) incubated with sera from control and CRF rats; and 3) the in vivo intracerebral accumulation of Chronic renal failure was induced by two-stage 5/6 nephrectomy as described previously (Leblond et al., 2001) . Every animal had ad libitum access to water, but to limit the effects of CRF-induced malnutrition, control pair-fed rats were fed the same amount of chow that CRF rats ate on the previous day. We have previously demonstrated that the caloric reduction in control animals induced by pair-feeding did not influence the expression of drug transporters (our unpublished data). At day 41 after nephrectomy, the rats were housed in metabolic cages, and urine was collected for 24 h to determine the clearance of creatinine. Rats were sacrificed by decapitation 42 days after nephrectomy for organ and blood collection or underwent a radiolabeled drug accumulation study. After the rats were sacrificed, the brain was immediately excised, rinsed in ice-cold saline, and flash-frozen in liquid nitrogen. Samples were stored at Ϫ80°C until membrane preparation or mRNA extraction. Blood was collected for the measurement of serum creatinine and urea and for bioassays with cultured RBECs and astrocytes.
Preparation of Crude Brain Membranes. Frozen rat brain biopsies (500 mg) were homogenized in 3 ml of homogenizing buffer (250 mM sucrose, 10 mM HEPES, and 10 mM Tris-HCl, pH 7.4) containing 0.1 mM PMSF using a Potter-Elvehjem tissue grinder (Wheaton Science Products, Millville, NJ). Differential centrifugation was used to obtain a crude membrane fraction (Chow et al., 2010) . In brief, the brain homogenates were centrifuged at 9000g for 10 min at 4°C. The supernatant was then spun at 33,000g for 60 min at 4°C, and the resulting pellet was resuspended in phosphate-buffered saline containing 0.1 mM PMSF. Samples were then sonicated on ice for 10 s to ensure homogeneity. Protein concentration was determined using the method of Lowry et al. (1951) , using bovine serum albumin as a reference protein.
Aliquots were stored at Ϫ80°C up to Western blot analysis.
Western Blot Analysis. Major brain drug transporters were assessed by Western blot analysis following a previously described protocol (Leblond et FIG. 1. Blood-brain barrier drug transporters. Mrp4 was found on the abluminal side of bovine brain capillaries where it is thought to mediate the efflux of molecules from the capillary cell into the brain, but this was not reported in rat and human brain (dashed line) Löscher and Potschka, 2005c; Deeken and Löscher, 2007; Oswald et al., 2007) . Oatps are widely known to be bidirectional transporters; the arrows indicate both directions (Löscher and Potschka, 2005c; Deeken and Löscher, 2007; Ohtsuki and Terasaki, 2007; Ose et al., 2010) . It was recently hypothesized that Oat3 mediates import and export from the brain (Ose et al., 2009 ). This figure is based on information published previously (Kikuchi et al., 2003; Mori et al., 2003; Kusuhara and Sugiyama, 2005; Löscher and Potschka, 2005c; Deeken and Löscher, 2007; Ohtsuki and Terasaki, 2007; Oswald et al., 2007; Eyal et al., 2009; Ose et al., 2009 ).
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P-gp and Mrp2 were detected using C219 and M 2 III-6 monoclonal antibodies (ID Labs Inc., London, ON, Canada), respectively. Oat3, Oatp2, and Oatp3 were detected using antibodies from Alpha Diagnostic International (San Antonio, TX). Anti-Bcrp was from Abbiotec (San Diego, CA), anti-Mrp4 was from Novus Biologicals, Inc. (Littleton, CO), and anti-Mrp5 was from Abnova (Walnut, CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used as a loading control, was detected using rabbit anti-GAPDH (Abcam Inc., Cambridge, MA).
mRNA Analysis. Total RNA was extracted from frozen tissue using TRIzol reagent (Invitrogen Canada Inc., Burlington, ON, Canada) according to the manufacturer's protocol. RNA concentration was determined by measuring absorbance at a wavelength of 260 nm. One microgram of total RNA was used to prepare cDNA by reverse transcription using the SuperScript VILO cDNA Synthesis kit (Invitrogen Canada Inc.). The mRNA encoding for P-gp (mdr1a), Mrp2, and Oatp2 was measured by quantitative real-time PCR as described previously (Naud et al., 2007 (Naud et al., , 2008 (Naud et al., , 2011 . Other genes were measured using appropriate TaqMan gene expression assays from Applied Biosystems (Foster City, CA). Table 1 shows the TaqMan gene expression assays used for the quantification of mRNA for each transporter. PCR products were analyzed using the ⌬⌬C T method (Livak and Schmittgen, 2001 ) using GAPDH as the standard gene.
In Vivo Accumulation of Radiolabeled Drugs in Brain. The intracerebral accumulation of radiolabeled drugs was used to determine the activity of the blood-brain barrier drug transporters. Four different drugs were tested: [ 14 C]benzylpenicillin, an antibiotic and a substrate for Oat3 and Mrps (Kikuchi et al., 2003; Choi et al., 2009); [ 3 H]digoxin, a cardiac glycoside and a substrate for Oatps and P-gp (Goralski et al., 2003) ; [ 14 C]doxorubicin, an anthracycline antibiotic used in cancer chemotherapy and a substrate of P-gp (Chan et al., 2004); and [ 3 H]verapamil, a calcium channel blocker and substrate of P-gp (Chan et al., 2004) . Digoxin (0.5 mg/kg) was administered via intraperitoneal injection, benzylpenicillin [control (CTL), 5 mg/kg; CRF, 1 mg/kg] was administered via intramuscular injection, and doxorubicin (5 mg/kg) (Hsieh et al., 2008) and verapamil (0.1 mg/kg) (Hendrikse et al., 1998) were administered in the tail vein. All were injected with an approximate 1:1500 hot/cold ratio so the milligram amount of radioactive compound would not factor into the final dosage calculation. To evaluate cerebral accumulation, similar plasma concentrations of drugs need to be attained, and therefore CRF rats received a lower dose of benzylpenicillin because of its reduced clearance in CRF. Rats were anesthetized using isoflurane 30 min (doxorubicin), 60 min (verapamil), or 2 h (benzylpenicillin and digoxin) after injection, and a cardiac puncture was performed to recover the maximum volume of blood in heparinized tubes to obtain plasma. Brains were harvested, rinsed in cold phosphate-buffered saline, weighted, minced, and placed in 2 ml of Solvable solution (PerkinElmer Life and Analytical Sciences, Waltham, MA) at 56°C overnight. Dissolved brain volumes were noted, and radioactivity was counted on a Wallac 1409 ␤-counter (PerkinElmer Life and Analytical Sciences) in 1 ml of dissolved brain tissue and 2 ml of plasma after the addition of 4 ml of ScintiSafe Plus Scintillant (Thermo Fisher Scientific, Waltham, MA). The results were calculated as a ratio between the radioactivity count (in counts per minute) for 1 g of brain tissue and the radioactivity count for 1 ml of plasma. The mean for the CTL groups was arbitrarily defined as 100%.
Effects of Uremic Serum on Brain Drug Transporters. To determine whether uremic serum could affect the expression and function of blood-brain barrier drug transporters, we incubated RBECs and astrocytes with serum from nephrectomized rats and evaluated the drug transporters' protein expression.
Isolation and Culture of Rat Astrocytes. Rat astrocytes were isolated and cultured as described previously by Perrière et al. (2005) and Booher and Sensenbrenner (1972) . When cells reached confluency, the standard culture medium was changed to culture medium containing 10% serum from either control or nephrectomized rats (one serum per flask). After 48 h of culture, the culture medium was recovered under sterile conditions to be used for RBEC conditioning, and cells were trypsinized, pelleted, and homogenized in phosphate-buffered saline containing 0.1 mM PMSF. Protein concentrations were determined using the Micro BCA Protein Assay kit (Thermo Fisher Scientific). One hundred micrograms was loaded for Western blot analysis of each studied transporter.
Isolation and Culture of RBECs. RBECs were isolated and puromycin purified for 72 h as published previously (Perrière et al., 2005) . Culture medium was then changed, for a 24-h period, to endothelial cell basal medium (ECBM) containing 20% bovine plasma-derived serum, 2 ng/ml basic fibroblast growth factor, 500 ng/ml hydrocortisone, and 1% Penstrep (a mixture of 20,000 U/mg penicillin and streptomycin) (Perrière et al., 2005) . Four days after seeding, the culture medium was again changed to a 50:50 mix of predescribed ECBM culture medium and culture medium recovered from astrocyte cultures containing 10% fetal bovine serum to simulate coculture with astrocytes. Finally, the culture medium was changed 48h later to a new 50:50 mix of predescribed ECBM containing 20% serum from CTL or nephrectomized rats and astrocyte preconditioned medium with sera from CTL of CRF rats. 8-(4-Chlorophenylthio)-cAMP (250 M) and the cAMP phosphodiesterase-4-specific inhibitor RO 20 1724 (17.5 M) were added to the final mix. After 48 h of culture, cells were trypsinized, pelleted, and homogenized in phosphate-buffered saline containing 0.1 mM PMSF. Protein concentrations were determined using the Micro BCA Protein Assay kit (Thermo Fisher Scientific). One hundred micrograms was loaded for Western blot analysis of each studied transporter.
Other Assays. Blood and urine chemistries were determined with an Architect C1600 clinical analyzer (Abbott Laboratories, Saint-Laurent, QC, Canada).
Statistical Analysis. Results are expressed as mean Ϯ S.D. Differences between groups were assessed using an unpaired Student's t test or an analysis of variance test. Significant analysis of variance was followed by a Scheffé's post hoc comparison of groups. The threshold of significance was p Ͻ 0.05. Table 2 presents the biochemical parameters and body weights of both groups of rats. Compared with control animals, CRF rats had higher levels of serum creatinine and urea and lower creatinine clearance (reduced by 80%; p Ͻ 0.001). There was no difference in body weight between control and CRF rats.
Results

Biochemical Parameters and Body Weight in Control and CRF Rats.
Protein Expression of Brain Drug Transporters in CRF Rats. Figure 2 presents the measured protein expression of various drug transporters in crude brain membranes of control and CRF rats. The expression level of Bcrp, Mrp2, Mrp4, Oat3, Oatp2, Oatp3, and P-gp was significantly decreased from 20 to 50% in CRF rat crude brain membranes as shown by Western blot. The only measured protein that remained stable was Mrp5. We found significant correlations between protein expression and the rat clearance of creatinine for Bcrp (r ϭ
TABLE 2
Characteristics of control and CRF rats
Data are the mean Ϯ S.D. Measurements were made at the time of sacrifice. Twenty-fourhour urinary collection was begun the day before. Blood urea and creatinine and urine creatinine were determined with an Architect C1600 clinical analyzer (Abbott Laboratories). Figure 3 presents results from the analysis of mRNA coding for brain drug transporters. There were significant decreases in the expression of Bcrp (35%), Mrp2 (40%), Mrp4 (30%), Oat3 (40%), Oatp2 (35%), Oatp3 (70%), and P-gp (35%) mRNA in CRF rat brain compared with controls. Again, only Mrp5 mRNA remained stable between the groups.
In Vivo Accumulation of Radiolabeled Drugs in the Brain of Rats with Surgically Induced Chronic Renal Failure. Two hours after administration, digoxin plasma radioactivity was similar in control and CRF rats, whereas the plasma radioactivity of benzylpenicillin was slightly elevated by 17% in CRF rats compared with control animals (Fig. 4) (Fig. 5 ). There was a significant decrease in the expression of Bcrp (40%), Mrp2 (25%), Mrp4 (45%), Oat3 (35%), Oatp2 (35%), Oatp3 (25%), and P-gp (30%) protein when incubated with CRF serum compared with controls. On the other hand, the expression of Mrp5 was unaltered. These results were similar to those obtained in vivo in CRF rats.
Protein Expression of Drug Transporters in Rat Astrocytes Incubated with Serum from CRF Rats. Protein expression of drug transporters was measured in rat astrocytes incubated for 48 h with serum from control or CRF animals (Fig. 6 ). Significant decreases in the expression of Bcrp (25%), Mrp2 (25%), Mrp4 (30%), Oat3 (60%), Oatp2 (40%), Oatp3 (50%), and P-gp (30%) protein were observed when incubated with CRF serum compared with controls. The expression of Mrp5 remained unaltered. These results were similar to those obtained in vivo in CRF rats.
Discussion
This study demonstrated a significant (20 -50%) decrease in protein and mRNA expression of Bcrp, Mrp2 and 4, Oat3, Oatp2 and 3, and P-gp in crude rat brain membranes from CRF rats compared with CTL rats, whereas Mrp5 was unchanged. Similar reductions were observed in RBECs and astrocytes incubated with serum from nephrectomized rat serum, compared with control. Influx and efflux drug transporter and CRF (filled bars) rats were standardized by dividing them by the value obtained for GAPDH. The standardized densitometry units of control rats were arbitrarily defined as 100%. Shown is the mean expression in rats expressed as percentage of controls Ϯ S.D. of 10 different rat sera in each group. ‫,ء‬ p Ͻ 0.05, ‫,ءء‬ p Ͻ 0.01, and ‫,ءءء‬ p Ͻ 0.001 compared with control rats .   FIG. 4 . In vivo accumulation of radiolabeled drugs in the brain of rats with surgically induced chronic renal failure. The brain/plasma radioactivity (in counts per minute) ratio for 1 g of brain tissue/1 ml plasma in CTL (open bars) and CRF (filled bars) rats is shown. CRF rats received one-fifth of the CTL rats' dose of benzylpenicillin but had a 17% (p Ͻ 0.05) higher plasma radioactivity of benzylpenicillin. However, with equal dosing between the groups, digoxin, doxorubicin, and verapamil plasma radioactivity was similar in the CTL and CRF rats. The mean ratio for CTL animals was arbitrarily defined as 100%. Data are expressed as mean Ϯ S.D. of at least three rats in each group. ‫,ءءء‬ p Ͻ 0.001 compared with CTL rats.
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at ASPET Journals on June 28, 2017 dmd.aspetjournals.org expression at the BBB and in the brain thus seem equally affected by CRF. For BBB permeability, we observed a 30% decrease in the BBB permeability to benzylpenicillin in nephrectomized rats and no change in the BBB permeability to digoxin, doxorubicin, and verapamil as measured by their brain/plasma radioactivity ratio.
We found significant correlations between the clearance of creatinine and the expression of all down-regulated transporters at the protein level, indicating that the changes in transporters are related to the severity of the renal failure. In addition, we have demonstrated that the modifications in drug transporter expression occurred in response to one or many factors present in the sera from uremic rats in at least two brain cell types, as demonstrated by the changes in protein expression of transporters in astrocytes and RBECs, which are similar to those observed in brain biopsies of CRF rats.
To our knowledge, no group has studied the impact of renal failure on the expression of brain drug transporters. However, many studies have reported a change in drug transporters in various organs in CRF (Huang et al., 2000; Laouari et al., 2001; Sun et al., 2004 Sun et al., , 2006 Naud et al., 2007 Naud et al., , 2008 Naud et al., , 2011 . In some of these studies, uremic circulating factors seemed involved in the expression and activity changes. Although no specific factor has been identified, many potential factors include uremic toxins such as CMPF, IS, or PAH and proinflammatory cytokines that are known to be elevated in CRF (Oettinger et al., 1994; Sunder-Plassmann et al., 1994; Ziesche et al., 1994; Akahoshi et al., 1995; Higuchi et al., 1997) . Indeed, uremic toxins have been shown to inhibit drug uptake by Oat1, Oat3, and Oatp2 in the rat liver, kidney, and brain (Deguchi et al., 2004 (Deguchi et al., , 2006 Sun et al., 2004 Sun et al., , 2006 . In addition, proinflammatory cytokines such as interleukin (IL)-1␤, IL-6, and tumor necrosis factor ␣ can modulate drug transporter expression and activity in various organs including at the BBB (Petrovic et al., 2007; Morgan et al., 2008) . For example, in vitro studies have demonstrated that IL-1␤ and IL-6 can decrease the expression of P-gp and Bcrp in brain capillary endothelial cells and that IL-6 can decrease P-gp expression in cultured rat astrocytes (Ronaldson and Bendayan, 2006; von Wedel-Parlow et al., 2009; Poller et al., 2010) . Proinflammatory cytokines could thus play a role in the BBB drug transporter expression down-regulation observed in CRF.
Despite significant decreases of brain transporter expression in CRF rats, we did not observe in vivo brain accumulation of three different substrates, namely digoxin, doxorubicin, and verapamil. Such a discrepancy has also been observed in inflammation studies. Indeed, previously published data demonstrated that systemic inflammation, as seen in CRF, moderately down-regulated (Ϫ24%) the protein expression of P-gp at the BBB 6 h after the induction of inflammation by endotoxin (Zhao et al., 2002) . In that study, P-gp expression returned to normal 24 h after inflammation (Zhao et al., 2002) . They observed increased plasma and brain concentrations of doxorubicin in mice 6 h after the induction of inflammation compared with control. However, endotoxin-induced systemic inflammation did not significantly change the brain/plasma concentration ratio of doxorubicin (Zhao et al., 2002) . The authors thus conclude that endotoxininduced systemic inflammation has no effect on BBB integrity and doxorubicin transport across the blood-brain barrier in mice (Zhao et al., 2002) . In addition, another study demonstrated that central nervous system inflammation produces a 50% decrease in P-gp mRNA expression and an almost 100% decrease in Oatp2 mRNA in the rat brain 6 h after induction (Goralski et al., 2003) . This group used [ 3 H]digoxin as a probe for P-gp function in vivo and observed, 6 and 24 h after inflammation induction, an increase in brain and plasma 3 H-radioactivity (Goralski et al., 2003) . However, the brain/plasma radioactivity ratio was unchanged (Goralski et al., 2003) . Based on these results, and because CRF is a state of chronic inflammation, it could explain why, like Zhao et al. (2002) and Goralski et al. (2003) , we observe decreased protein and mRNA expression of P-gp and Oatp2 in the brain of nephrectomized rats but no intracerebral accumulation of digoxin, doxorubicin, or verapamil.
We also observed a 30% decrease in the BBB permeability to benzylpenicillin in nephrectomized rats compared with controls as measured by the total brain/plasma radioactivity ratio. In vitro, studies showed that benzylpenicillin is a substrate of Mrp2 and Oat3, but no blood-to-brain transporter has been identified (Kikuchi et al., 2003; Choi et al., 2009) . As mentioned previously, Oat3 is involved in the transport of uremic toxins from the brain (Ohtsuki et al., 2002; Kikuchi et al., 2003; Tahara et al., 2005; Deguchi et al., 2006) . In fact, this transporter is typically thought to play a role in the efflux of drugs from the brain. However, a recent study hypothesized that it is also involved in the uptake of 3R,4R,5S-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, from the blood to the brain (Ose et al., 2009 ). Thus, it could be responsible for the bloodto-brain uptake of substrates, such as benzylpenicillin, or uremic toxins and for their brain-to-blood transport. This hypothesis is supported by a study performed in the 1960s that demonstrated that probenecid, a well known Oat3 inhibitor, limits the entry of benzylpenicillin into rat brain as shown by a decrease in brain/plasma concentration ratio of benzylpenicillin when coadministered with probenecid (Fishman, 1966) . The 30% decrease in the brain/blood radioactivity ratio of benzylpenicillin observed in the brain of nephrectomized rats indicates a more efficient efflux of the drug compared with its uptake. However, Mrp2 (efflux) and Oat3 (influx and efflux) were equally reduced by 40% in the brain of nephrectomized rats compared with controls. If the hypothesis of Oat3 involvement in the blood-tobrain influx of benzylpenicillin and uremic toxins is correct, the greater functional reduction in benzylpenicillin brain uptake could be attributed to competition with accumulating uremic toxins such as CMPF, IS, and PAH for blood-to-brain transport by Oat3, preventing benzylpenicillin entry into the brain. However, it is also possible that Mrp2 plays a more important functional role in the BBB permeability of benzylpenicillin, causing a greater efflux of the drug compared with its influx.
In conclusion, although we reported significant reductions in the expression of influx and efflux brain drug transporters, it seems that the BBB integrity and permeability to drugs is preserved in renal failure as shown by the unchanged intracerebral accumulation of digoxin, doxorubicin, and verapamil and by the reduced accumulation of benzylpenicillin.
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